Pathology of Castleman Disease.

[1]  J. Manning,et al.  Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells. , 2017, Pathology.

[2]  N. Hijiya,et al.  Classical Hodgkin lymphoma and Castleman disease: a rare morphologic combination. , 2017, Blood.

[3]  J. Rossi,et al.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. , 2017, Blood.

[4]  K. Young,et al.  Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. , 2017, Blood.

[5]  Y. Natkunam,et al.  HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report—Part 3 , 2017, American journal of clinical pathology.

[6]  A. Perrot,et al.  Hodgkin Lymphoma and Castleman Disease: When One Blood Disease Can Hide Another , 2017, Case reports in hematology.

[7]  E. Jaffe,et al.  Multicentric Castleman disease: Where are we now? , 2016, Seminars in diagnostic pathology.

[8]  Dermot Kelleher,et al.  Idiopathic multicentric Castleman's disease: a systematic literature review. , 2016, The Lancet. Haematology.

[9]  T. Yoshino,et al.  Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman disease , 2016, American journal of hematology.

[10]  Vinodh Pillai,et al.  TAFRO syndrome or Castleman-Kojima syndrome: a variant of multicentric Castleman disease. , 2015, Blood.

[11]  N. Munshi,et al.  Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease , 2015, Clinical Cancer Research.

[12]  N. Munshi,et al.  Use of a claims database to characterize and estimate the incidence rate for Castleman disease , 2015, Leukemia & lymphoma.

[13]  J. Rossi,et al.  Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Oncology.

[14]  L. Medeiros,et al.  Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease , 2014, Modern Pathology.

[15]  F. van Rhee,et al.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. , 2014, Blood.

[16]  E. Jaffe,et al.  Increased CD5‐positive polyclonal B cells in Castleman disease: a diagnostic pitfall , 2013, Histopathology.

[17]  M. Kojima,et al.  Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012 , 2013, Journal of clinical and experimental hematopathology : JCEH.

[18]  Tomomi Sato,et al.  Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? , 2013, Journal of clinical and experimental hematopathology : JCEH.

[19]  S. Jagannath,et al.  A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease , 2013, Clinical Cancer Research.

[20]  É. Oksenhendler,et al.  Human herpesvirus 8-related Castleman disease in the absence of HIV infection. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  K. Takata,et al.  Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. , 2013, Journal of clinical and experimental hematopathology : JCEH.

[22]  K. Schulte,et al.  Surgery in Castleman's Disease: A Systematic Review of 404 Published Cases , 2012, Annals of surgery.

[23]  K. Schulte,et al.  Castleman's disease: systematic analysis of 416 patients from the literature. , 2011, The oncologist.

[24]  R. Brynes,et al.  B-cell lymphoma with hyaline vascular Castleman disease-like features: a clinicopathologic study. , 2011, American journal of clinical pathology.

[25]  G. Fernandes,et al.  Cytology of Castleman disease hyaline vascular type: a close differential diagnosis with Hodgkin's lymphoma. , 2010, Acta cytologica.

[26]  R. Warnke,et al.  Castleman Disease: An Update on Classification and the Spectrum of Associated Lesions , 2009, Advances in anatomic pathology.

[27]  N. Nishimoto,et al.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.

[28]  F. Pagani,et al.  Interfollicular Hodgkin's lymphoma and Castleman's disease , 2006, Histopathology.

[29]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[30]  A. Hagemeijer,et al.  Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. , 2002, The American journal of surgical pathology.

[31]  G. Dewald,et al.  Lack of Cytogenetic Abnormalities in Castleman's Disease* , 2001, Southern medical journal.

[32]  S. Pittaluga,et al.  Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. , 2001, Blood.

[33]  P. D. Dal Cin,et al.  A chromosomal abnormality in hyaline vascular Castleman's disease: evidence for clonal proliferation of dysplastic stromal cells. , 2000, The American journal of surgical pathology.

[34]  O. Lin,et al.  Angiomyoid and follicular dendritic cell proliferative lesions in Castleman's disease of hyaline-vascular type: a study of 10 cases. , 1997, The American journal of surgical pathology.

[35]  C. Fletcher,et al.  Follicular dendritic cell sarcoma , 1997, Cancer.

[36]  F. Sigaux,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.

[37]  C. Fellbaum,et al.  Castleman's disease. Differences in follicular dendritic network in the hyaline vascular and plasma cell variants , 1994, Histopathology.

[38]  J. Chan,et al.  Follicular dendritic cell tumor and vascular neoplasm complicating hyaline-vascular Castleman's disease. , 1994, The American journal of surgical pathology.

[39]  B. Klein,et al.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. , 1994, The New England journal of medicine.

[40]  L. Medeiros,et al.  Hodgkin's disease with coexistent Castleman-like histologic features. A report of three cases. , 1994, Archives of pathology & laboratory medicine.

[41]  P. Maheswaran,et al.  Hodgkin's disease presenting with the histological features of Castleman's disease , 1991, Histopathology.

[42]  J. Diebold,et al.  Interleukin-6 gene expression in Castleman's disease. , 1991, Blood.

[43]  A. Nienhuis,et al.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. , 1990, The Journal of clinical investigation.

[44]  R. Scully,et al.  Case records of the Massachusetts General Hospital. , 1990 .

[45]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease , 1989 .

[46]  E. Ishii,et al.  Giant lymph node hyperplasia (castleman's disease) with spontaneous production of high levels of b‐cell differentiation factor activity , 1989, Cancer.

[47]  K. Lennert,et al.  Monoclonality and polyclonality of plasma cells in Castleman's disease of the plasma cell variant , 1989, Histopathology.

[48]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.

[49]  G. Frizzera.  Castleman's disease and related disorders. , 1988, Seminars in diagnostic pathology.

[50]  B. Peterson,et al.  Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus. , 1988, The American journal of pathology.

[51]  B. Peterson,et al.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  P. Banks,et al.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Pathological findings in 15 patients , 1983, The American journal of surgical pathology.

[53]  R. Stein,et al.  Multicentric giant lymph node hyperplasia. , 1978, American journal of clinical pathology.

[54]  B. Castleman,et al.  Hyaline‐vascular and plasma‐cell types of giant lymph node hyperplasia of the mediastinum and other locations , 1972 .

[55]  B. Castleman,et al.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. , 1972, Cancer.

[56]  K. Inada,et al.  Localized Mediastinal Lymph‐Node Hyperplasia Resembling Thymoma , 1958, Annals of surgery.

[57]  B. Castleman,et al.  Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. , 1954, The New England journal of medicine.